Exo Therapeutics, Inc.

[Sidebar#SC145549] Biopharmaceutical companies and other life science start-ups may access $1.28bn in new venture capital available through four different sources, including Eir Venture Partners AB’s

Exo Therapeutics, Inc. launched in December with $25m in series A venture capital and has advanced its ExoSight technology platform far enough since then to justify a $78m series B round that the com

Biopharmaceutical companies developing therapies for neurological diseases are in the midst of a boom, not only in terms of novel approaches to treating intractable diseases but also in terms of attra